Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Etalocib is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase. It has antineoplastic activities.
Description | Etalocib is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase. It has antineoplastic activities. |
Synonyms | LY293111, VML295 |
Molecular Weight | 544.61 |
Formula | C33H33FO6 |
CAS No. | 161172-51-6 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 100 mg/mL (183.62 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Etalocib 161172-51-6 G蛋白偶联受体 凋亡 免疫与炎症 Apoptosis Leukotriene Receptor LTR antiinflammatory LY 293111 VML-295 VML 295 inhibit VML295 LY-293111 Pulmonary Inhibitor asthma bronchiectasis LY293111 inhibitor